None listed
Conditions
Brief summary
Evidence supports the use of intra-operative antiseptic rinse in breast implant surgery to minimize the risk of capsular contracture or other complications. However, there is limited consensus or standardization of antiseptic rinse in practice. Having already determined contemporary trends in antiseptic rinse use in primary breast device surgery in Australia, we will use observational Australian Breast Device Registry (ABDR) data to analyse antiseptic rinse effects on clinical outcomes.
Interventions
The intervention is the use of intraoperative betadine (Povidone-Iodine) pocket rinse. All surgeons and hospital sites registered with the ABDR continue to report any implant-related surgeries to the ABDR on an ongoing basis. Follow-up/outcomes data are made up of explantation (removal of implant) surgeries made necessary by the respective post-operative complications. All follow-up surgeries reported to the ABDR will be obtained up to 31 Dec 2022 from the ABDR, allowing for a 'rolling' minimum follow-up period of 2 years. Patients are not required to do anything above their usual surgical treatment journey. The reporting of operative data is inherent in the ABDR national reporting processes.
Sponsors
Eligibility
Inclusion criteria
Primary (First) Breast device surgery between 1 Jan 2015 to 31 Dec 2020 as reported to the ABDR
Exclusion criteria
Device revision surgeries Tissue expander insertion Tissue expander removal and implant insertion Concurrent mastectomy Axillary surgery including sentinel node biopsy Concurrent flap cover